Graduated from Peking University Health Science Center in 2005 with a Bachelor's degree in Clinical Medicine. In the same year, was recommended for a combined Master's and Doctoral program in Oncology, under the supervision of Professor Hao Chunyi, and obtained a Doctorate in Oncology in 2010. Joined the Second Department of Hepatobiliary and Pancreatic Surgery at Peking University Cancer Hospital in 2010. Served as a visiting scholar at Cardiff University School of Medicine in the UK in 2012. Specializes in surgical treatment and preoperative conversion therapy for complex diseases such as pancreatic cancer, cholangiocarcinoma, liver cancer, and retroperitoneal tumors. Currently serves as Standing Committee Member and Secretary-General of the Pancreatic Cancer Committee of the Chinese Society of Clinical Oncology (CSCO), Member of the Pancreatic Disease Committee of the Chinese Research Hospital Association, Member of the Youth Committee of the Liver Tumor Branch of the China International Exchange and Promotive Association for Medical and Health Care, Member of the Critical Care Medicine Committee of the Beijing Anti-Cancer Association, Member of the Pancreatic Tumor Branch of the "Chinese Digestive Surgery Elite Club", and Member of the Ethics Committee of Peking University Cancer Hospital. Has led one project funded by the Beijing Natural Science Foundation and is responsible for multiple clinical studies on hepatocellular carcinoma. In 2013, won the Excellence Award and Outstanding Surgical Case in the "Enjoy My Surgery - National Liver Surgery Video Exchange Summit". In 2016, represented the Hepatobiliary Tumor MDT Team of Peking University Cancer Hospital in the "Liver Cancer Treatment Experience PK National Finals" and won an award. In 2018, received the Youth Innovation Award in the "Revere Life - 2018 Glorious Doctor" event hosted by People's Daily. Published Papers: Wu J, Li C, Liu B, et al. Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study[J]. Annals of Translational Medicine, 2023, 11(5). Jia W W, Wu J H, Yang C, et al. An additional gastrojejunostomy may reduce the incidence of moderate and severe delayed gastric emptying after distal segmental duodenectomy for gastrointestinal stromal tumors[J]. World Journal of Surgical Oncology, 2024, 22(1): 303. Jia W, Wu J, Zhang H, et al. Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma[J]. Therapeutic Advances in Medical Oncology, 2024, 16: 17588359241276968. Li S, Zhang H, Yu H, et al. Combination of eribulin and anlotinib exerts synergistic cytotoxicity in retroperitoneal liposarcoma by inducing endoplasmic reticulum stress[J]. Cell Death Discovery, 2024, 10(1): 355.